• Thu, August 25, 2022
• Wed, August 24, 2022
Salim Syed Maintained (BBIO) at Strong Buy with Decreased Target to $23 on, Aug 24th, 2022
Salim Syed of Mizuho, Maintained "BridgeBio Pharma, Inc." (BBIO) at Strong Buy with Decreased Target from $25 to $23 on, Aug 24th, 2022.
Salim has made no other calls on BBIO in the last 4 months.
There are 2 other peers that have a rating on BBIO. Out of the 2 peers that are also analyzing BBIO, 0 agree with Salim's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Salim
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Increased Target to $30 on, Tuesday, July 26th, 2022
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $19 on, Tuesday, May 24th, 2022
Like: 👍
